Engineered Salmonella typhimurium expressing E7 fusion protein, derived from human papillomavirus, inhibits tumor growth in cervical tumor-bearing mice
- Authors
- Yoon, Wonsuck; Choi, Ji Hyeon; Kim, Sinyeon; Park, Yong Keun
- Issue Date
- 2월-2014
- Publisher
- SPRINGER
- Keywords
- Anti-tumor effect; Cancer therapy; Cervical cancer; HPV 16 E7; Human papillomavirus; Salmonella typhimurium; Tumor retardation
- Citation
- BIOTECHNOLOGY LETTERS, v.36, no.2, pp.349 - 356
- Indexed
- SCIE
SCOPUS
- Journal Title
- BIOTECHNOLOGY LETTERS
- Volume
- 36
- Number
- 2
- Start Page
- 349
- End Page
- 356
- URI
- https://scholar.korea.ac.kr/handle/2021.sw.korea/99395
- DOI
- 10.1007/s10529-013-1370-8
- ISSN
- 0141-5492
- Abstract
- The tumor-suppressing effects of SipB160/HPV16 E7 fusion protein, derived from human papillomavirus, and expressed in Salmonella enterica serovar typhimurium, were evaluated in a cervical cancer model. The expressed E7 protein resulted in efficacious cytotoxicity and tumor growth retardation in TC-1 cervical cancer cells. In addition, in mice bearing TC-1 tumors, live cells of Salmonella expressing HPV16 E7 were administered orally and induced immune responses through interferon-gamma and tumor necrosis factor-alpha cytokine secretion and also suppressed tumor growth (45 %) and prolonged survival (70 %) compared with the control group. These results suggested that the SipB160/HPV16 E7 fusion protein may be a candidate cancer therapeutic agent.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - ETC > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.